BAF60c and abdominal aortic aneurysm
BAF60c 和腹主动脉瘤
基本信息
- 批准号:10650179
- 负责人:
- 金额:$ 54.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Abdominal Aortic AneurysmAddressAffectAgeAneurysmAngiotensin IIAortaApoptosisAtherosclerosisAttentionAttenuatedAutomobile DrivingBlood VesselsCardiovascular systemCatalytic DomainCathepsinsCell SeparationCellsCellular biologyChIP-seqChromatinChromatin Remodeling FactorChromatin StructureCo-ImmunoprecipitationsComplementComplexContractile ProteinsDNADataDevelopmentDiabetes MellitusElastasesElderlyEligibility DeterminationEnergy MetabolismEnvironmentEpigenetic ProcessExtracellular Matrix DegradationFamilyFamily memberFunctional disorderGene ExpressionGenesHeartHomeostasisHumanHyperlipidemiaHypertensionIn VitroIncidenceIndividualInflammationInflammatoryKnock-in MouseKnock-outKnockout MiceLigandsLinkLipidsLoxP-flanked alleleMMP9 geneMapsMedialMediatingMedicalMetabolicMolecularMusOperative Surgical ProceduresOutcomePathogenesisPathologicPathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPhenotypePlayPrevalencePrimary PreventionProcessPromoter RegionsReceptor SignalingRegulationReportingRisk FactorsRoleRuptureSamplingSchemeSex DifferencesSmokingSmooth Muscle MyocytesStainsStimulusSucroseTherapeuticThoracic Aortic AneurysmTissue SampleTissuesTransducersTransgenic MiceTranslatingVascular Smooth MuscleViral VectorWorkabdominal aortabrahmachromatin remodelingdifferential expressiongain of functiongenetic associationgenomic locusgranulocytehigh riskin vivoin vivo Modelinsightknock-downloss of functionmalemembermortalitymortality riskmouse modelnovelnovel therapeuticsp65preventpromoterprotein expressionrecruitrepairedresponsesextherapeutic targettranscription factortranscriptome sequencingvascular inflammation
项目摘要
PROJECT SUMMARY/ABSTRACT
Abdominal Aortic Aneurysm (AAA) is a primary medical concern due to the increasing prevalence and high
mortality rate upon rupture. Although vascular inflammation, extracellular matrix (ECM) degradation, and
subsequent vascular smooth muscle cells (VSMCs) apoptosis are pathologic features and drivers of AAA,
efforts to manipulate these processes did not yet result in any effective drug therapies beyond primary
prevention, creating an urgent need for new drug-based therapeutic strategies. This will be facilitated by a
deeper and comprehensive understanding of the molecular and cellular mechanisms driving onset,
progression, and outcomes of AAA. Chromatin remodeling altering gene expression has been linked to most
pathophysiologic conditions, including atherosclerosis and diabetes, but its role in AAA remains largely
unknown. The BAF60 family comprises three mutually exclusive subunits of the SWItch/Sucrose Non-
Fermentable (SWI/SNF) chromatin remodeling complex. Of relevance to the cardiovascular field, they play
essential roles in controlling lipid homeostasis, energy metabolism (BAF60a), granulocyte (BAF60b) and heart
(BAF60c) development. We found that BAF60a, b and c are differentially expressed in human and mouse AAA
tissues, suggesting a potential role of the BAF60 subunits in VSMC biology and the development of AAA. We
recently reported that loss of BAF60a in VSMCs prevents experimental AAA by reducing vascular inflammation
and ECM degradation in mice. Remarkably, BAF60c is the most abundant BAF60 subunit expressed in VSMC.
Our preliminary data show that BAF60c is downregulated in the abdominal aortic aneurysmal tissue in both
humans and mice. VSMC BAF60c knockout significantly aggravates elastase-induced AAA, and knockdown of
BAF60c in human aortic smooth muscle cells reduced the SMC contractile protein expression and increased
inflammatory genes and MMP9 expression. We hypothesize that VSMC-specific BAF60c attenuates AAA
development by maintaining the VSMC contractile phenotype, and inhibiting vascular inflammation and ECM
degradation. Using gain- and loss-of-function in HASMCs in vitro, AAA-relevant stimuli, our unique VSMC-
specific BAF60c knockout and transgenic mice, two established murine AAA models in vivo, and an integrated
workflow, we will (Aim 1) Demonstrate that VSMC-specific BAF60c attenuates AAA formation with attention to
altered cellular profiles and intercellular cross-talk by scRNAseq and provide proof-of-concept for therapeutic
targeting and (Aim 2) Determine the protective mechanisms of BAF60c in VSMC homeostasis in vitro using
relevant stimuli and RNAseq, ChIP-seq and co-immunoprecipitation. This work will provide unique mechanistic
insights on how various and varying risk factors translate into VSMC dysfunction leading to AAA and provide
the basis for developing novel therapies for AAA.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jifeng Zhang其他文献
Jifeng Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jifeng Zhang', 18)}}的其他基金
Novel methods to improve nuclease mediated homologous recombination, Administrative suppl
改进核酸酶介导的同源重组的新方法,行政补充
- 批准号:
10640401 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:
Kruppel-like factor 11 (KLF11) and atherosclerosis
Kruppel 样因子 11 (KLF11) 和动脉粥样硬化
- 批准号:
9924279 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
- 批准号:
10615626 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改进核酸酶介导的同源重组的新方法
- 批准号:
9345608 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
- 批准号:
10383251 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Research Grant














{{item.name}}会员




